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management of benign and 
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ABSTRACT
Thyroglobulin (Tg) is the major glycoprotein produced by the thyroid gland, where it serves as a 
template for thyroid hormone synthesis and as an intraglandular store of iodine. Measurement of Tg 
levels in serum is of great practical importance in the follow-up of differentiated thyroid carcinoma 
(DTC), a setting in which elevated levels after total thyroidectomy are indicative of residual or recur-
rent disease. The most recent methods for serum Tg measurement are monoclonal antibody-based 
and are highly sensitive. However, major challenges remain regarding the interpretation of the re-
sults obtained with these immunometric methods, particularly in patients with endogenous antithy-
roglobulin antibodies or in the presence of heterophile antibodies, which may produce falsely low 
or high Tg values, respectively. The increased prevalence of antithyroglobulin antibodies in patients 
with DTC, as compared with the general population, raises the very pertinent possibility that tumor 
Tg may be more immunogenic. This inference makes sense, as the tumor microenvironment (tumor 
cells plus normal host cells) is characterized by several changes that could induce posttranslational 
modification of many proteins, including Tg. Attempts to understand the structure of Tg have been 
made for several decades, but findings have generally been incomplete due to technical hindrances 
to analysis of such a large protein (660 kDa). This review article will explore the complex structure of 
Tg and the potential role of its marked heterogeneity in our understanding of normal thyroid biology 
and neoplastic processes. Arch Endocrinol Metab. 2016;60(1):66-75
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INTRODUCTION
T hyroglobulin (Tg) is a high molecular mass pro-tein produced exclusively by the thyroid follicu-
lar cells. Measurement of Tg levels in serum is of great 
clinical importance in medical practice, as part of the 
diagnostic workup for several benign conditions, but 
especially in the postoperative follow-up of differenti-
ated thyroid cancer (DTC).
Under normal conditions, only a very small amount 
of Tg bypasses intrathyroidal proteolysis and reaches the 
bloodstream in essentially intact form. Therefore, only 
with the advent of radioimmunoassay techniques in the 
late 1960s did measurement of the minute concentra-
tions of Tg occurring in human serum become possible 
(1,2). This method was brought into routine use in the 
early 1970s, with the studies of Van Herle and cols. (3). 
However, the advent of monoclonal antibodies led to 
a great progress in this field, enabling the development 
of more modern, automated, non-isotopic, two-site as-
says. These techniques revolutionized DTC follow-up, 
because of their high sensitivity (4) and their ability to 
detect concentrations of Tg as low as 0.1 ng/mL. This 
fact has made serum Tg measurement a cornerstone of 
post-thyroidectomy follow-up of patients with DTC, as 
Tg levels contribute to the definition of cure, residual 
disease, and even tumor recurrence (5,6). 
Although modern assays based on monoclonal anti-
Tg antibodies (TgAb) have enabled the development 
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of highly sensitive and specific measurement tech-
niques, some pitfalls persist in clinical practice. One 
of these drawbacks would be the variability between 
assays using different monoclonal antibodies, which 
may cause Tg levels to have an up to two-fold differ-
ence when the same sample is analyzed by different 
assays, even in the absence of endogenous TgAb (4). 
In addition, some assays may recognize differences be-
tween normal Tg and tumor-derived Tg (7). With the 
majority of current assays, the presence of endogenous 
TgAb in the serum of patients with DTC can interfere 
with test results, usually producing low and/or unde-
tectable Tg levels, which limits the use of serum Tg 
as a marker for follow-up of these patients (8,9). The 
exact mechanism of such interference is still unknown 
but may involve steric hindrance and/or masking of 
epitopes, events that hinders the recognition of Tg by 
reporter antibodies (10). This limitation is a particular 
concern because 25-30% of patients with DTC have 
circulating TgAb, a three times greater prevalence than 
that found in the general population (4). This gives 
rise to some pertinent speculation: a) could tumor Tg 
be structurally anomalous and, consequently, more 
immunogenic? Or b) could the “economy” of tumor 
cells, which are more prone to proliferation and expan-
sion, drive production of “naked” Tg, with simplified 
or even absent posttranslational modifications (iodin-
ation, glycosylation, sulfation) and, thus, bearing a 
greater number of exposed antigenic sites?
Attempts to elucidate the structure of Tg date back 
to the 1950s. Since then, evidence has arisen that se-
rum Tg is composed of a pool of polypeptide fragments 
which are highly heterogeneous in terms of size, but 
also exhibit differences in iodine content and in the dis-
tribution of glycosylation, and sulfation (11,12). How-
ever, technical limitations at that time, compounded by 
the very high molecular mass of Tg, made these initial 
studies somewhat incomplete. A critical step toward a 
better understanding of the structure of Tg was made 
in 1985, when its peptide sequence was described (11). 
This enabled new discoveries, such as the identification 
of new posttranslational modifications to its primary 
structure, and contributed to the development and 
enhancement of immunoassays for its detection. More 
recently, the “omics” era has created new perspectives 
for expansion of our knowledge of the structure of Tg, 
but many challenges remain (13). This review article 
will explore several aspects of Tg biosynthesis, with an 
emphasis on posttranslational processes, and their po-
tential role in the development, diagnosis, and manage-
ment of thyroid diseases.
STRUCTURE OF THYROGLOBULIN
Tg is synthesized in the endoplasmic reticulum of the 
follicular cells, modified in the Golgi complex and se-
creted into the follicular lumen. The gene that codes 
for Tg has been mapped to chromosome 8. It is fairly 
conserved across mammal species, with some sequence 
homology between human Tg and that of other ani-
mals (11). Tg is known to being enhanced with species 
development. Recent comparative phylogenetic analy-
ses of Tg from echinoderms, amphibians, zebrafish, and 
vertebrates provide evidence of the continued evolution 
of this protein (14).
Tg messenger RNA codes for a polypeptide chain 
consisting of 2,768 amino acid residues that will com-
pose the backbone of a high molecular weight glyco-
protein made up of two 330-kDa polypeptide chains. 
Mature Tg (660 kDa) is formed by linking two disul-
fide-bonds polypeptide chains (15,16).
Tg is divided into two regions: N-terminal and C-
terminal (Figure 1). These regions are so distinct that it 
has been suggested that the Tg gene was formed by the 
fusion of two different ancestral genes (17).
The first 19 residues of the N-terminal end consti-
tute the signal peptide, which directs the pre-polypep-
tide during posttranslational processing and secretion 
into the Golgi complex (9,14) (Figure 1).
Analysis of the polypeptide chain at the N-terminal 
end (1-2170) reveals an organized structure (Figure 1).
There are three domain types in which the positions 
of cysteine residues are highly conserved. By forming 
disulfide bonds between monomers, these residues in-
crease molecular stability and resistance to proteolysis 
(14). These domain types are: type 1, composed of ap-
proximately 50 residues which repeat 10 times between 
amino acids 1 and 1200; type 2, composed of 14-17 
residues that repeat three times between positions 1436 
and 1483; and type 3, which is composed of two sub-
types (A and B) that repeat five times between positions 
1583 and 2170 (16). It has been speculated that each 
of these regions has a different function, with region 1 
controlling Tg binding to other proteins; region 2 con-
trolling cell adhesion; and region 3 playing a structural 
role (14).
Conversely, the C-terminal region (approximately 
581 residues) does not exhibit internal homology, but 
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it is similar to a protein in the acetylcholinesterase family 
(carboxylesterase, type B) (17). Furthermore, this part 
of the molecule has reduced cysteine and increased ty-
rosine content as compared with the rest of the mono-
mer. Studies have shown that the acetylcholinesterase-
like region works as a dimerization domain to facilitate 
intracellular transport (18) (Figure 1).
TG AND THYROID HORMONOGENESIS
Tg accounts for over 75% of all thyroid proteins, and it 
is present in the colloid and in much of the intracellular 
material of the gland (16).
The physiologic functions of Tg include providing a 
matrix for thyroid hormone synthesis and storing iodine 
in the form of the iodinated tyrosyl residues monoiodo-
tyrosine (MIT) and diiodotyrosine (DIT), which are 
the precursors of the thyroid hormones T3 (triiodothy-
ronine) and T4 (thyroxine). In addition, Tg also plays a 
role in modulating the expression of genes involved in 
the synthesis of other thyroid proteins (sodium-iodide 
symporter [NIS] and thyroid peroxidase [TPO]) and 
transcription factors involved in normal thyroid physi-
ology (TTF-1, TTF-2, and PAX-8) (19,20).
In addition to these physiologic roles, Tg is in-
volved in the pathogenesis of several thyroid diseases, 
particularly autoimmune thyroiditis (in which it acts as 
an antigen) and DTC; in patients with DTC, Tg is used 
as a marker of residual disease or tumor recurrence after 
total thyroidectomy (5,6).
Figure 1. Schematic representation of the TG gene and polypeptide chain of human thyroglobulin (Tg). (A) Structure of the TG gene. Nucleotides are 
shown in black, and exons coding for the repeat domains and C-terminal portion are shown in red. (B) Structure of the Tg polypeptide chain (2749 amino 
acids). The signal peptide is shown in orange at the N-terminal portion, which is well-organized and divided into 3 major domains: type 1, encoded by 
exons 2-17 and composed of 10 repeats of a 50-amino acid sequence; type 2, encoded by exons 20-21 and composed of three repeats of 14-17 amino 
acid residues; and type 3, encoded by exons 23-37 and composed of 2 subtypes, a and b, which repeat 5 times and contain approximately 100 amino 
acids each. The C-terminal portion is not similarly organized and exhibits sequence homology to proteins in the acetylcholinesterase family (AChase-Like). 
(C) Schematic representation of the polypeptide sequence. Glycosylation sites are shown in green and iodination sites represented by purple triangles. 
Adapted from van de Graaf and cols. (16) and Vali and cols. (21).
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As noted above, Tg is the matrix for thyroid hor-
mone synthesis. This process begins with formation 
of the polypeptide chain within the endoplasmic re-
ticulum and continues with posttranslational modifica-
tions, which occur simultaneously: glycosylation and 
sulfation (primarily in the Golgi complex), iodination 
(in the thyrocyte apical membrane), and phosphoryla-
tion (in a yet-unknown compartment, but possibly the 
Golgi complex) (21,22). The critical stage of thyroid 
hormone synthesis is iodination, in which Tg must be 
directed to the follicular lumen and bind to the apical 
membrane of the follicle, where tyrosyl residues will be 
iodinated in a reaction catalyzed by TPO activated by 
hydrogen peroxide. The lumen is also the site of the 
coupling reaction, whereby two DIT residues or one 
MIT and one DIT residues fuse to form T4 and T3 
respectively. Iodinated Tg returns to the cell by endo-
cytosis; Tg-containing intracellular vesicles fuse with ly-
sosomes, where they will be acted upon by cathepsins, 
aminopeptidases, and dipeptidyl peptidases to release 
T4 and T3, which are then secreted into the blood-
stream (23). This entire hormonogenesis process is 
regulated primarily by the action of thyroid-stimulating 
hormone (TSH) (Figure 2).
POSTTRANSLATIONAL MODIFICATIONS TO TG
Tg undergoes extensive posttranslational modifications, 
including glycosylation, iodination, and phosphoryla-
tion. These modifications influence several aspects of 
normal Tg and thyroid hormone biosynthesis and play 
roles in various pathologic processes.
Figure 2. Schematic model of synthesis and posttranslational modifications of thyroglobulin (Tg) in the follicular cell. The two 330-kDa polypeptide chains, 
linked by disulfide bonds, are synthesized in the endoplasmic reticulum from mRNA transcribed from the TG gene, located on chromosome 8. 
Posttranslational modifications (glycation, sulfation, and phosphorylation) take place in the Golgi apparatus. Tg is then secreted into the colloid, where 
iodination occurs to form the thyroid hormone precursors MIT and DIT. Iodinated Tg enters the follicular cell cytoplasm by pinocytosis and combines with 
lysosomal vesicles containing proteolytic enzymes, which lyse Tg and release the thyroid hormones into the bloodstream. Part of the remaining material 
is reused by the cell.
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GLYCOSYLATION
Approximately 10% of the molecular mass of Tg is com-
posed of carbohydrate residues (21). The glycosylation 
process may occur via two basic mechanisms catalyzed 
by glycosyltransferases, namely, addition of N-linked 
and O-linked sugars. The bonding of sugars to Tg 
occurs step by step during transport of the nascent 
polypeptide chain from the endoplasmic reticulum to 
the Golgi complex (24) (Figure 2).
The major basic types of N-linked sugars are type A, 
or simple, which contain mannose and N-acetylglucos-
amine residues; and type B, or complex, which contain 
galactose, fucose, and sialic acid residues in addition 
to those of type A sugars. Other types include type C, 
which contain O-linked sugars, the residues of which 
are still largely unknown; and type D, which contain 
chains of the proteoglycan chondroitin sulfate. Type A 
and B sugars bind to Tg via asparagine residues, where-
as type C and D sugars bind to serine residues (21).
Oligosaccharides play roles in several thyroid func-
tions. Notable roles include: influence on iodination 
and hormone synthesis; specific interactions with mi-
crosomes and membrane receptors; directing Tg to 
subcellular and extracellular compartments (24); Tg 
immunoreactivity (25); and protein folding and recy-
cling (26). Sialic acid does not participate in hormono-
genesis, but it is essential for Tg binding to its trans-
membrane transporter and influences its solubility and 
immunoreactivity (27).
Regarding the immunoreactivity of Tg, Fenouillet 
and cols. compared the Tg secreted by cells in culture 
to that extracted from thyroid tissues and found that 
the former exhibited fourfold less binding to polyclonal 
antibodies against native Tg. This difference was at-
tributed to the greater amount of complex branched 
carbohydrates on secreted Tg as compared with thy-
roid-derived Tg. These carbohydrate chains appear to 
interfere with antigen-antibody recognition by mask-
ing regions of the polypeptide chain that constitute the 
main antigenic determinants (25). Another possibility 
is that carbohydrates may distort the structure of the 
glycoprotein and thus weaken antigen-antibody inter-
actions. Salabè and cols. also assessed the influence of 
glycosylation on Tg immunoreactivity, finding that im-
munoreactivity increases after desialylation, which sug-
gests that sialic acid masks antigens (27).
Despite advances, much remains to be explored re-
garding Tg glycosylation.
SULFATION
Sulfation is a late posttranslational modification that ta-
kes place in the Golgi complex (Figure 2). Sulfate resi-
dues are present in carbohydrate units and in some ami-
no acids, especially tyrosine (28). The sulfate residues 
of Tg are essentially present in complex carbohydrates, 
particularly in chondroitin sulfate chains, an event that 
only occurs in human Tg (29). 
The role of these sulfated residues varies. They are 
involved in molecular conformation and protein inter-
actions, take part in activation and deactivation of bio-
logical activities, and account for much of the negative 
charge of the Tg molecule (10,30). However, these 
roles have yet to be fully elucidated and little is known 
regarding their regulation, although investigators have 
reported that TSH downregulates Tg sulfation (31).
A role of sulfate in tumor dissemination and growth 
mechanisms has been speculated. Loss of sulfate has 
been documented in some tumor models, including 
pancreatic cancer (32). Furthermore, Emoto and cols. 
(33) found decreased sulfation in Tg derived from 
papillary thyroid cancer (PTC) cells as compared with 
normal Tg, and believed this might influence tumor 
growth.
PHOSPHORYLATION
Phosphorylation of Tg probably takes place in the Golgi 
complex, but its mechanism is still largely unclear (Figu-
re 2). Studies conducted in the 1980s (22) found that 
approximately 50% of phosphate present in Tg is co-
valently bound to carbohydrate chains, 30% to serine 
residues, and the remaining 20% to tyrosine. The role 
of phosphorylation of sugar residues is unclear, but, by 
analogy to other proteins, phosphorylation of mannose 
residues may be involved in directing Tg through the 
Golgi complex to the endosomes and, finally, to the ly-
sosomes, where it is degraded for iodothyronine release 
and recycling of amino acids (34). The role of serine and 
tyrosine residue phosphorylation is even less clear. In 
vitro studies conducted on FRTL-5 cells and using dog 
thyroid-derived Tg have suggested a potential role of 
this posttranslational modification in the Tg iodination 
process and in TSH-independent protein synthesis (35).
IODINATION
Tg contains a variable amount of iodine, which de-
pends on the availability of this element in the body. 
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The percentage of iodine in Tg by mass ranges from 
0.1% to 1% across several species (21). Iodine trans-
port to the thyroid is a two-stage process. The first in-
volves the sodium/iodide-symporter (NIS), which is 
found in the basolateral membrane and actively trans-
ports iodine from the bloodstream into the follicular 
cells. In the second stage, which involves pendrin, a 
protein found at the apical membrane, iodine is trans-
ported from the cytoplasm to the follicle lumen, whe-
re it is stored for later use in the synthesis of thyroid 
hormones (21).
Iodination takes place in the follicular lumen, spe-
cifically at the thyrocyte apical membrane, to which io-
dine is transported and where it is bound to tyrosine 
residues to form MIT or DIT. This reaction is cata-
lyzed by TPO and requires hydrogen peroxide, which 
is generated by NADPH-dependent oxidase (21). As 
noted above, this is followed by the coupling reaction, 
also catalyzed by TPO, whereby one MIT and one DIT 
molecule fuse to form T3 or two DIT molecules fuse 
to form T4.
The structure of Tg contains approximately 130-
140 tyrosine residues, only 25-40 of which undergo 
iodination, and even fewer of which take part in the 
coupling reaction (21). Studies of Tg in different spe-
cies have reported four main sites of hormonogenesis 
(A-D) and three secondary sites (G, N, and F), with 
elevated sequence similarity among species. Utilization 
of these sites varies depending on the origin of Tg and 
it is influenced by the availability of iodine (21).
Iodination might play a role in the immunogenicity 
of Tg, as does glycosylation. A study showed that the 
affinity of specific anti-native Tg monoclonal antibodies 
decreases with a reduction in the iodine content of the 
protein (36). However, another study suggests that the 
iodine content of the Tg molecule may alter its con-
formation, changing the structure of its polypeptides 
and its antigenic characteristics according to the type 
of monoclonal antibody used for its detection (37). 
Furthermore, iodine is necessary for the recognition of 
certain antigens, and thus contributes to the pathogen-
esis of autoimmune thyroiditis (36). There is a certain 
degree of uncertainty about the difference between io-
dine content in tumor Tg compared with normal Tg. 
Tumor Tg has a much less amount of iodine than that 
of normal Tg, whereas there is no difference in the io-
dine content of serum Tg from patients with benign 
and malignant tumors when compared to that from 
normal subjects (38). 
TG HETEROGENEITY AND THYROID DISEASE
Studies have shown differences in Tg across several be-
nign thyroid diseases. Saboori and cols. showed that 
normal Tg and thyroid-derived Tg from patients with 
Graves’ disease exhibit distinct profiles when analyzed 
by ion exchange chromatography. Unlike normal Tg, 
the Tg of Graves’ disease has a greater proportion of 
protein fragments with low affinity for ion exchange 
columns, a difference the authors attributed to the lo-
wer iodine content of these polypeptides. Furthermo-
re, these under-iodinated forms of Tg showed decrea-
sed reactivity to monoclonal TgAb on Western blot 
analysis (39).
Other studies have demonstrated that different 
peptide segments of Tg react in specific ways with sera 
from patients with autoimmune thyroiditis. This sug-
gests that the polypeptide structure of certain Tg frag-
ments has a conformational arrangement associated 
with increased antigenicity, and may thus contribute to 
the pathogenesis of autoimmune thyroid diseases (40).
Regarding thyroid neoplasms, attempts to isolate 
distinct epitopes capable of distinguishing normal Tg 
from carcinoma-derived Tg or Tg from benign thyroid 
diseases have been made for decades. Several studies in-
vestigated differences in Tg solubility, electrophoretic 
behavior, and iodine and carbohydrate content (38,41-
43). These potential physicochemical changes have also 
been associated with differences in the antigenicity of 
tumor-derived Tg as compared with normal Tg. In 
1984, Kohno and cols. showed that a certain monoclo-
nal anti-Tg antibody profile was unable to distinguish 
between normal Tg and Tg from patients with Graves’ 
disease, follicular adenoma, or follicular carcinoma, but 
exhibited very weak binding to Tg from patients with 
papillary carcinoma (44). This distinction did not ap-
pear to be attributable to differences in Tg iodine con-
tent between each disease, but rather to potential minor 
alterations in the amino acid sequence and/or polysac-
charide structure of the protein. In a more recent study, 
Magro and cols. showed that papillary carcinoma-de-
rived Tg contained high levels of keratan sulfate, and 
suggested that this phenomenon could even be used 
to distinguish papillary cancer from benign thyroid 
diseases, in which expression of this heteropolysaccha-
ride is negligible (45). In addition, Emoto and cols. 
found that papillary carcinoma-derived Tg contained 
chondroitin sulfate, a glycosaminoglycan found exclu-
sively in human Tg, and exhibited very little sulfation 
as compared with Tg derived from normal tissue (33). 
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These changes in glycosylation pattern are consistent 
with previous studies of other tumors and reinforce the 
hypothesis of involvement of these modifications both 
in carcinogenesis and in increased antigenicity of aber-
rant forms of Tg (46,47).
TG HETEROGENEITY: CLINICAL APPLICATIONS 
AND FUTURE PERSPECTIVES
As noted at the start of this review, measurement of 
Tg levels in serum plays an essential role in the follow-up 
of patients with DTC after thyroidectomy. In this set-
ting, increased Tg levels are indicative of residual or 
recurrent disease, whereas undetectable Tg levels and 
elevated TSH levels strongly suggest that the patient is 
disease-free.
However, serum Tg measurement is subject to 
interference due to the presence of heterophile anti-
bodies (such as human anti-mouse antibody) or en-
dogenous TgAb. The latter are much more prevalent 
in patients with DTC (25-30%) than in the healthy 
population (10%) (4). As mentioned before, the rea-
son for this discrepancy is unknown; however, consid-
ering the wide range of posttranslational modifications 
present in tumor-derived Tg, one may speculate that 
these changes may contribute to increased antigenicity. 
Recent findings of Lupoli and cols. seem to support 
this hypothesis (48). In their study, TgAb from pa-
tients with DTC had a distinct specificity for different 
epitopes of Tg when compared with TgAb from pa-
tients with Hashimoto’s thyroiditis, possibly reflecting 
the presence of an abnormal Tg in patients with DTC 
(48). However, even the most modern assays available 
for Tg measurement cannot avoid this interference; 
i.e., both immunometric methods (immunoradiomet-
ric and immunochemiluminometric assays) and Tg 
recovery tests generally yield falsely low results when 
TgAb are present in the sample (49).
The presence of these endogenous anti-Tg antibo-
dies in the follow up of DTC is an additional clinical 
challenge and may cause some degree of uncertainty 
either to the physician, regarding the status of the 
disease, or to the patient, causing anxiety, besides the 
increase in treatment costs due to the higher number 
of laboratory and imaging tests. Previous studies have 
shown that higher titers of anti-Tg antibodies are as-
sociated with higher risk of recurrence and have found 
that the higher the levels of these antibodies, the higher 
the chances of tumor recurrence (50-52). Although the 
presence of antibodies hinders the use of Tg as a follow-
up marker, in some cases the serial TgAb measurements 
function as a surrogate marker (53). Thus, the majority 
of patients with DTC and positive TgAb tend to exhibit 
a progressive decline in titers of these antibodies, and 
a new increase in antibody levels may be considered a 
sign of tumor recurrence (52,53). However, anti-Tg 
antibody positivity itself does not correlate directly with 
worse prognosis, unless titers increase progressively. In 
fact, it is the trend of serum concentration of TgAb, 
i.e., if it is downward or upward, which will define pa-
tient outcomes (53). Regardless of the implications of 
this phenomenon, the reappearance of anti-Tg anti-
bodies in these patients is an additional indicator of the 
increased antigenicity of tumor-derived Tg.
Another issue encountered in clinical practice is the 
wide variability in results when different methods are 
used for Tg measurement (4). As these methods may 
employ monoclonal antibodies that target distinct epi-
topes of Tg, it is not unusual to find marked disparities 
between Tg values during follow-up when different as-
says are used for Tg measurement (4,9). Furthermore, 
monoclonal antibodies are produced from normal 
thyroid-derived Tg, and strong evidence suggests that 
plasma-derived Tg, particularly that produced by tu-
mors, may contain epitopes distinct from those present 
in tissue-derived Tg. This creates an additional prob-
lem, which is the possibility of false-negative Tg mea-
surements in the presence of active disease (49,54).
Several methods have been proposed in an attempt 
to bypass this issue, such as measurement of Tg mRNA 
in peripheral blood (55), use of liquid chromatography 
tandem mass spectrometry (LC-MS/MS) to detect Tg 
in serum (10), detection of methylation markers (56), 
and serum measurement of TSH receptor mRNA (57), 
but none is sufficiently sensitive for clinical use. Addi-
tional strategies already used in the diagnostic investi-
gation of other neoplasms, such as circulating tumor 
cell detection (58) and cancer cell exosome analysis 
(59), are very appealing, but have yet to become estab-
lished methods in DTC.
One of the most promising attempts to escape the 
interference of TgAb on the Tg dosage is LC-MS/MS. 
In this technique, the entire serum protein is degraded 
with trypsin and the levels of Tg-specific peptides are 
used as a reference to quantify Tg (10). Although po-
tentially specific, this analysis still poses difficult chal-
lenges to solve. Initially, this method has low sensitivity 
(detects Tg in the range of 0.5-1.0 ng/mL) compared 
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with current immunoassays. Another challenge has 
been to enrich the sample under analysis with the tryp-
sinized fragments of serum Tg from patients with DTC 
before analysis by LC-MS/MS, since tumor Tg does 
not necessarily would generate, after trypsin digestion, 
peptide sequences with the same charge/mass ratio of 
that from standard Tg used as reference. 
Thus, the question remains whether polymorphisms 
in the Tg gene modifying the primary polypeptide se-
quence of the protein may affect the generation of tar-
get peptides to be identified by LC-MS/MS. In prac-
tice, this could really be a problem in view of recent 
studies that found two phenomena that may change the 
primary polypeptide sequence of Tg: different single-
nucleotide polymorphisms in the Tg gene leading to 
an amino acid exchange (60) and somatic mutations in 
tumor cells (2.7%) in a significant number of patients 
with DTC (61). Tg gene may carry several polymor-
phisms and some of them have been associated with 
autoimmune thyroid disease (62). Besides, different 
TG RNA splicing forms from different human thyroid 
tissues have also been described in tumor samples and 
this kind of variation seems to be of high frequency, 
even in normal thyroid tissue (63). 
In addition, any posttranslational modifications may 
also cause loss of peptides of interest, preventing their 
identification by LC-MS/MS and resulting in falsely 
low or even negative values  in the presence of disease. 
It is important to notice that in order for the genera-
tion of appropriate peptides to be impaired, it is suf-
ficient that any posttranslational modification produces 
a trypitc fragment with a different charge/mass ratio, 
thus preventing its recognition by LC-MS/MS analysis 
(10). An example for these interferences would be seen 
in one of two peptides specifically targeted for LC-MS/
MS, VIFDANAPVAVR, which is considered well con-
served and protected from posttranslational modifica-
tion (64). This peptide (located at amino acid position 
1579-1590 of thyroglobulin) contains an Asparagine in 
its structure, an amino acid that is glycosylated in nor-
mal human Tg (16). Although polymorphism at this 
position is rare (< 0.01%, rs141316336), other varia-
tions in the region flanking this peptide, and shortly 
beyond, could change the type of amino acid and then 
potentially interfere on the site for trypsin action. 
Besides, even if a hypothetic patient with metastatic 
thyroid tumor produces a Tg with this exact peptide 
sequence but with no glycosylation at Arginine posi-
tion, this peptide will not be detected by LC-MS/MS. 
In fact, a recent study by Spencer and cols. showed the 
limitations of Tg identification by LC-MS/MS; this 
strategy, for example, fails to detect serum Tg levels in 
nearly one fourth of patients with positive TgAb and 
persistent/recurrent disease (65). In that report, the 
authors proposed two theories to explain this fail: the 
presence of polymorphisms in tumor-derived Tgs pre-
venting the generation of target peptide; or an increased 
clearance of Tg-anti-Tg complexes that has been hy-
pothesized for a long time (66-68). However, it is im-
portant to note that despite initial difficulties, LC-MS/
MS already represents a major advance over immunoas-
says in which the disease is not detected in more than 
98% of cases (65). One possibility to overcome this new 
challenge may be the development of a wider panel of 
proteotypic peptides, which could increase the sensitiv-
ity and specificity of LC-MS/MS assays, thus reducing 
the likelihood of false-negative results.
Despite the aforementioned issues, Tg measure-
ment remains the cornerstone of follow-up of patients 
with DTC. Therefore, new techniques that can enhance 
its detection are essential. Modern methods, particu-
larly those involving proteomics and mass spectrometry 
analysis (69), may hold the key to the identification of 
anomalous tumor-derived forms of Tg and thus enable 
the development of more specific assays that can con-
tribute to diagnosis, follow-up, and prognostication of 
DTC.
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